NAPSRx News: Johnson & Johnson (Janssen) Intends to File More than 10 New Products by 2019

WASHINGTON - May 21, 2015 - PRLog -- Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines. This strategic move by J&J is fueled by the success of their existing pharmaceutical portfolio which has consistently surpassed sales expectations and has been a core contributor to the company’s earnings growth.

The therapeutic areas of concentration include: – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology.  Since 2009, Janssen has launched 14 new products, seven of which have already exceeded sales expectations and is estimated to incur revenue in excess of $1 billion during 2015. The launch of these new products in addition to the company’s in market portfolio will provide the driving force to maintain above-industry compound annual growth through 2019.

The company’s late stage products projected to drive revenue growth for the next several years, pending regulatory approval include: daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C. Janssen plans to submit a Biologic Licensing Application to the FDA this year for daratumumab in double refractory multiple myeloma, based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.

“In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines,” said Joaquin Duato, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “We are working with our partners to advance the innovative products in our pipeline and to deliver significant benefits to patients.”

In 2014, the total pharmaceutical market experienced a 40 percent growth incurring $1 trillion from specialty medicines, including oncology, autoimmune, respiratory and anti-viral medications. In 2014, Johnson & Johnson’s pharmaceutical business (Janssen) had an operational increase of 16.5 percent compared to 2013 with sales of $32.3 billion.  According to IMS Health, the total global branded pharmaceuticals market will increase at compound annual operational growth rate of approximately 3 percent from 2014 to 2019.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. The NAPSRx® provides the CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/